Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 464

1.

Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues.

Meehan CJ, Goig GA, Kohl TA, Verboven L, Dippenaar A, Ezewudo M, Farhat MR, Guthrie JL, Laukens K, Miotto P, Ofori-Anyinam B, Dreyer V, Supply P, Suresh A, Utpatel C, van Soolingen D, Zhou Y, Ashton PM, Brites D, Cabibbe AM, de Jong BC, de Vos M, Menardo F, Gagneux S, Gao Q, Heupink TH, Liu Q, Loiseau C, Rigouts L, Rodwell TC, Tagliani E, Walker TM, Warren RM, Zhao Y, Zignol M, Schito M, Gardy J, Cirillo DM, Niemann S, Comas I, Van Rie A.

Nat Rev Microbiol. 2019 Jun 17. doi: 10.1038/s41579-019-0214-5. [Epub ahead of print] Review.

PMID:
31209399
2.

Mycobacterium tuberculosis lineage 1 genetic diversity in Pará, Brazil, suggests common ancestry with east-African isolates potentially linked to historical slave trade.

Conceição EC, Refregier G, Gomes HM, Olessa-Daragon X, Coll F, Ratovonirina NH, Rasolofo-Razanamparany V, Lopes ML, van Soolingen D, Rutaihwa L, Gagneux S, Bollela VR, Suffys PN, Duarte RS, Lima KVB, Sola C.

Infect Genet Evol. 2019 Jun 3;73:337-341. doi: 10.1016/j.meegid.2019.06.001. [Epub ahead of print]

PMID:
31170529
3.

WGS more accurately predicts susceptibility of Mycobacterium tuberculosis to first-line drugs than phenotypic testing.

Jajou R, van der Laan T, de Zwaan R, Kamst M, Mulder A, de Neeling A, Anthony R, van Soolingen D.

J Antimicrob Chemother. 2019 May 22. pii: dkz215. doi: 10.1093/jac/dkz215. [Epub ahead of print]

PMID:
31119271
4.

GWAS for quantitative resistance phenotypes in Mycobacterium tuberculosis reveals resistance genes and regulatory regions.

Farhat MR, Freschi L, Calderon R, Ioerger T, Snyder M, Meehan CJ, de Jong B, Rigouts L, Sloutsky A, Kaur D, Sunyaev S, van Soolingen D, Shendure J, Sacchettini J, Murray M.

Nat Commun. 2019 May 13;10(1):2128. doi: 10.1038/s41467-019-10110-6.

5.

Role and value of whole genome sequencing in studying tuberculosis transmission.

Nikolayevskyy V, Niemann S, Anthony R, van Soolingen D, Tagliani E, Ködmön C, van der Werf MJ, Cirillo DM.

Clin Microbiol Infect. 2019 Apr 11. pii: S1198-743X(19)30124-7. doi: 10.1016/j.cmi.2019.03.022. [Epub ahead of print] Review.

PMID:
30980928
6.

Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014.

Karo B, Kohlenberg A, Hollo V, Duarte R, Fiebig L, Jackson S, Kearns C, Ködmön C, Korzeniewska-Kosela M, Papaventsis D, Solovic I, van Soolingen D, van der Werf MJ.

Euro Surveill. 2019 Mar;24(12). doi: 10.2807/1560-7917.ES.2019.24.12.1800392.

7.

SNP-IT Tool for Identifying Subspecies and Associated Lineages of Mycobacterium tuberculosis Complex.

Lipworth S, Jajou R, de Neeling A, Bradley P, van der Hoek W, Maphalala G, Bonnet M, Sanchez-Padilla E, Diel R, Niemann S, Iqbal Z, Smith G, Peto T, Crook D, Walker T, van Soolingen D.

Emerg Infect Dis. 2019 Mar;25(3):482-488. doi: 10.3201/eid2503.180894.

8.

The respiratory microbiota: new insights into pulmonary tuberculosis.

Eshetie S, van Soolingen D.

BMC Infect Dis. 2019 Jan 25;19(1):92. doi: 10.1186/s12879-019-3712-1.

9.

Global expansion of Mycobacterium tuberculosis lineage 4 shaped by colonial migration and local adaptation.

Brynildsrud OB, Pepperell CS, Suffys P, Grandjean L, Monteserin J, Debech N, Bohlin J, Alfsnes K, Pettersson JO, Kirkeleite I, Fandinho F, da Silva MA, Perdigao J, Portugal I, Viveiros M, Clark T, Caws M, Dunstan S, Thai PVK, Lopez B, Ritacco V, Kitchen A, Brown TS, van Soolingen D, O'Neill MB, Holt KE, Feil EJ, Mathema B, Balloux F, Eldholm V.

Sci Adv. 2018 Oct 17;4(10):eaat5869. doi: 10.1126/sciadv.aat5869. eCollection 2018 Oct.

10.

Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.

CRyPTIC Consortium and the 100,000 Genomes Project, Allix-Béguec C, Arandjelovic I, Bi L, Beckert P, Bonnet M, Bradley P, Cabibbe AM, Cancino-Muñoz I, Caulfield MJ, Chaiprasert A, Cirillo DM, Clifton DA, Comas I, Crook DW, De Filippo MR, de Neeling H, Diel R, Drobniewski FA, Faksri K, Farhat MR, Fleming J, Fowler P, Fowler TA, Gao Q, Gardy J, Gascoyne-Binzi D, Gibertoni-Cruz AL, Gil-Brusola A, Golubchik T, Gonzalo X, Grandjean L, He G, Guthrie JL, Hoosdally S, Hunt M, Iqbal Z, Ismail N, Johnston J, Khanzada FM, Khor CC, Kohl TA, Kong C, Lipworth S, Liu Q, Maphalala G, Martinez E, Mathys V, Merker M, Miotto P, Mistry N, Moore DAJ, Murray M, Niemann S, Omar SV, Ong RT, Peto TEA, Posey JE, Prammananan T, Pym A, Rodrigues C, Rodrigues M, Rodwell T, Rossolini GM, Sánchez Padilla E, Schito M, Shen X, Shendure J, Sintchenko V, Sloutsky A, Smith EG, Snyder M, Soetaert K, Starks AM, Supply P, Suriyapol P, Tahseen S, Tang P, Teo YY, Thuong TNT, Thwaites G, Tortoli E, van Soolingen D, Walker AS, Walker TM, Wilcox M, Wilson DJ, Wyllie D, Yang Y, Zhang H, Zhao Y, Zhu B.

N Engl J Med. 2018 Oct 11;379(15):1403-1415. doi: 10.1056/NEJMoa1800474. Epub 2018 Sep 26.

11.

Prevalence and Characterization of Heterogeneous Variable-Number Tandem-Repeat Clusters Comprising Drug-Susceptible and/or Variable Resistant Mycobacterium tuberculosis Complex Isolates in the Netherlands from 2004 to 2016.

Roof I, Jajou R, Kamst M, Mulder A, de Neeling A, van Hunen R, van der Hoek W, van Soolingen D.

J Clin Microbiol. 2018 Oct 25;56(11). pii: e00887-18. doi: 10.1128/JCM.00887-18. Print 2018 Nov.

12.

Tuberculosis after a borderline QuantiFERON result during screening before infliximab.

Uzorka JW, Delfos NM, Witte AMC, Scheper H, van Soolingen D, Arend SM.

Eur Respir J. 2018 Aug 2;52(2). pii: 1800913. doi: 10.1183/13993003.00913-2018. Print 2018 Aug. No abstract available.

PMID:
30072541
13.

The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.

Zhang M, Wang S, Wilffert B, Tong R, van Soolingen D, van den Hof S, Alffenaar JW.

Br J Clin Pharmacol. 2018 Dec;84(12):2747-2760. doi: 10.1111/bcp.13722. Epub 2018 Oct 3. Review.

14.

The problem of resistance in Mycobacterium tuberculosis may be underestimated in Africa.

B Cadmus SI, Falodun OI, Fagade OE, Murphy R, Taiwo B, Van Soolingen D.

Int J Mycobacteriol. 2018 Apr-Jun;7(2):148-151. doi: 10.4103/ijmy.ijmy_29_18.

15.

Correction: Epidemiological links between tuberculosis cases identified twice as efficiently by whole genome sequencing than conventional molecular typing: A population-based study.

Jajou R, de Neeling A, van Hunen R, de Vries G, Schimmel H, Mulder A, Anthony R, van der Hoek W, van Soolingen D.

PLoS One. 2018 May 14;13(5):e0197556. doi: 10.1371/journal.pone.0197556. eCollection 2018.

16.

Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.

Zuur MA, Pasipanodya JG, van Soolingen D, van der Werf TS, Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 13;67(11):1743-1749. doi: 10.1093/cid/ciy346.

PMID:
29697766
17.

Epidemiological links between tuberculosis cases identified twice as efficiently by whole genome sequencing than conventional molecular typing: A population-based study.

Jajou R, de Neeling A, van Hunen R, de Vries G, Schimmel H, Mulder A, Anthony R, van der Hoek W, van Soolingen D.

PLoS One. 2018 Apr 4;13(4):e0195413. doi: 10.1371/journal.pone.0195413. eCollection 2018. Erratum in: PLoS One. 2018 May 14;13(5):e0197556.

18.

Tuberculosis treatment outcomes in Ethiopia from 2003 to 2016, and impact of HIV co-infection and prior drug exposure: A systematic review and meta-analysis.

Eshetie S, Gizachew M, Alebel A, van Soolingen D.

PLoS One. 2018 Mar 19;13(3):e0194675. doi: 10.1371/journal.pone.0194675. eCollection 2018. Review.

19.

'Happy the man, who, studying nature's laws, Thro' known effects can trace the secret cause.' Do we have enough pieces to solve the pyrazinamide puzzle?

Anthony RM, den Hertog AL, van Soolingen D.

J Antimicrob Chemother. 2018 Jul 1;73(7):1750-1754. doi: 10.1093/jac/dky060.

PMID:
29528413
20.

Correction: Variability and cost implications of three generations of the Roche LightCycler® 480.

Dullaert-de Boer M, Akkerman OW, Vermeer M, Hess DLJ, Kerstjens HAM, Anthony RM, van der Werf TS, van Soolingen D, van der Zanden AGM.

PLoS One. 2018 Feb 9;13(2):e0192946. doi: 10.1371/journal.pone.0192946. eCollection 2018.

21.

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.

Akkerman OW, Grasmeijer F, de Lange WCM, Kerstjens HAM, de Vries G, Bolhuis MS, Alffenaar JW, Frijlink HW, Smith G, Gajraj R, de Zwaan R, Hagedoorn P, Dedicoat M, van Soolingen D, van der Werf TS.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702490. doi: 10.1183/13993003.02490-2017. Print 2018 Mar. No abstract available.

22.

Measuring tuberculosis transmission in low-incidence countries.

de Vries G, van Dissel J, van Soolingen D.

Lancet Respir Med. 2018 Apr;6(4):e13. doi: 10.1016/S2213-2600(18)30042-0. Epub 2018 Feb 2. No abstract available.

PMID:
29398474
23.

Pound foolish and penny wise-when will dosing of rifampicin be optimised?

Magis-Escurra C, Anthony RM, van der Zanden AGM, van Soolingen D, Alffenaar JC.

Lancet Respir Med. 2018 Apr;6(4):e11-e12. doi: 10.1016/S2213-2600(18)30044-4. Epub 2018 Jan 29. No abstract available.

PMID:
29396032
24.

Variability and cost implications of three generations of the Roche LightCycler® 480.

Dullaert-de Boer M, Akkerman OW, Vermeer M, Hess DLJ, Kerstjens HAM, Anthony RM, van der Werf TS, van Soolingen D, van der Zanden AGM.

PLoS One. 2018 Jan 12;13(1):e0190847. doi: 10.1371/journal.pone.0190847. eCollection 2018. Erratum in: PLoS One. 2018 Feb 9;13(2):e0192946.

25.

In Vitro Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin.

Dijkstra JA, van der Laan T, Akkerman OW, Bolhuis MS, de Lange WCM, Kosterink JGW, van der Werf TS, Alffenaar JWC, van Soolingen D.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01724-17. doi: 10.1128/AAC.01724-17. Print 2018 Mar.

26.

Donor-derived tuberculosis via orthotopic liver transplantation.

Ruijter BN, van Wijngaarden AKS, van Hoek B, Mensen M, van Soolingen D, Arend SM.

Neth J Med. 2017 Nov;75(9):415-417.

27.

Performance of Xpert MTB/RIF Ultra: a matter of dead or alive.

Arend SM, van Soolingen D.

Lancet Infect Dis. 2018 Jan;18(1):8-10. doi: 10.1016/S1473-3099(17)30695-3. Epub 2017 Dec 5. No abstract available.

28.

A Predominant Variable-Number Tandem-Repeat Cluster of Mycobacterium tuberculosis Isolates among Asylum Seekers in the Netherlands and Denmark, Deciphered by Whole-Genome Sequencing.

Jajou R, de Neeling A, Rasmussen EM, Norman A, Mulder A, van Hunen R, de Vries G, Haddad W, Anthony R, Lillebaek T, van der Hoek W, van Soolingen D.

J Clin Microbiol. 2018 Jan 24;56(2). pii: e01100-17. doi: 10.1128/JCM.01100-17. Print 2018 Feb.

29.

Occurrence and Nature of Double Alleles in Variable-Number Tandem-Repeat Patterns of More than 8,000 Mycobacterium tuberculosis Complex Isolates in The Netherlands.

Jajou R, Kamst M, van Hunen R, de Zwaan CC, Mulder A, Supply P, Anthony R, van der Hoek W, van Soolingen D.

J Clin Microbiol. 2018 Jan 24;56(2). pii: e00761-17. doi: 10.1128/JCM.00761-17. Print 2018 Feb.

30.

Membrane Filtration Is Suitable for Reliable Elimination of Mycobacterium tuberculosis from Saliva for Therapeutic Drug Monitoring.

van den Elsen SHJ, van der Laan T, Akkerman OW, van der Zanden AGM, Alffenaar JC, van Soolingen D.

J Clin Microbiol. 2017 Nov;55(11):3292-3293. doi: 10.1128/JCM.01248-17. Epub 2017 Aug 9. No abstract available.

31.

Multidrug-resistant/extensively drug-resistant tuberculosis in Greece: predominance of Mycobacterium tuberculosis genotypes endemic in the Former Soviet Union countries.

Ioannidis P, van Soolingen D, Mokrousov I, Papaventsis D, Karabela S, Konstantinidou E, Marinou I, Nikolaou S, Kanavaki S, Mantadakis E, Samonis G, Anthony R, Vogiatzakis E.

Clin Microbiol Infect. 2017 Dec;23(12):1002-1004. doi: 10.1016/j.cmi.2017.07.002. Epub 2017 Jul 8. No abstract available.

32.

Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia.

Sengstake S, Bergval IL, Schuitema AR, de Beer JL, Phelan J, de Zwaan R, Clark TG, van Soolingen D, Anthony RM.

BMC Infect Dis. 2017 Jul 12;17(1):491. doi: 10.1186/s12879-017-2594-3.

33.

Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.

van Rijn SP, Srivastava S, Wessels MA, van Soolingen D, Alffenaar JC, Gumbo T.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e02039-16. doi: 10.1128/AAC.02039-16. Print 2017 Sep.

34.

Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment.

Anthony RM, Cynamon M, Hoffner S, Werngren J, den Hertog AL, van Soolingen D.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00258-17. doi: 10.1128/AAC.00258-17. Print 2017 Jun. No abstract available.

35.

Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.

Van't Boveneind-Vrubleuskaya N, Seuruk T, van Hateren K, van der Laan T, Kosterink JGW, van der Werf TS, van Soolingen D, van den Hof S, Skrahina A, Alffenaar JC.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00343-17. doi: 10.1128/AAC.00343-17. Print 2017 Aug.

36.

Genomic characterization of Mycobacterium tuberculosis lineage 7 and a proposed name: 'Aethiops vetus'.

Nebenzahl-Guimaraes H, Yimer SA, Holm-Hansen C, de Beer J, Brosch R, van Soolingen D.

Microb Genom. 2016 Jun 24;2(6):e000063. doi: 10.1099/mgen.0.000063. eCollection 2016 Jun.

37.

Association between genotype and drug resistance profiles of Mycobacterium tuberculosis strains circulating in China in a national drug resistance survey.

Zhou Y, van den Hof S, Wang S, Pang Y, Zhao B, Xia H, Anthony R, Ou X, Li Q, Zheng Y, Song Y, Zhao Y, van Soolingen D.

PLoS One. 2017 Mar 23;12(3):e0174197. doi: 10.1371/journal.pone.0174197. eCollection 2017.

38.

Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis.

Van der Paardt AL, Akkerman OW, Gualano G, Palmieri F, Davies Forsman L, Aleksa A, Tiberi S, de Lange WC, Bolhuis MS, Skrahina A, van Soolingen D, Kosterink JG, Migliori GB, van der Werf TS, Alffenaar JC.

Eur Respir J. 2017 Mar 22;49(3). pii: 1601612. doi: 10.1183/13993003.01612-2016. Print 2017 Mar. No abstract available.

39.

Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis.

van Altena R, Dijkstra JA, van der Meer ME, Borjas Howard JF, Kosterink JG, van Soolingen D, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e01400-16. doi: 10.1128/AAC.01400-16. Print 2017 Mar.

40.

Whole genome sequencing as the ultimate tool to diagnose tuberculosis.

van Soolingen D, Jajou R, Mulder A, de Neeling H.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S60-S61. doi: 10.1016/j.ijmyco.2016.10.036. Epub 2016 Nov 24.

41.

Transmissible Mycobacterium tuberculosis Strains Share Genetic Markers and Immune Phenotypes.

Nebenzahl-Guimaraes H, van Laarhoven A, Farhat MR, Koeken VACM, Mandemakers JJ, Zomer A, van Hijum SAFT, Netea MG, Murray M, van Crevel R, van Soolingen D.

Am J Respir Crit Care Med. 2017 Jun 1;195(11):1519-1527. doi: 10.1164/rccm.201605-1042OC.

42.

Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis.

Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D.

Lancet Infect Dis. 2017 Feb;17(2):223-234. doi: 10.1016/S1473-3099(16)30407-8. Epub 2016 Nov 17. Review.

PMID:
27865891
43.

Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly.

van Altena R, Akkerman OW, Alffenaar JC, Kerstjens HA, Magis-Escurra C, Boeree MJ, van Soolingen D, de Lange WC, Bolhuis MS, Hoefsloot W, de Vries G, van der Werf TS.

Eur Respir J. 2016 Dec;48(6):1800-1802. doi: 10.1183/13993003.01208-2016. Epub 2016 Oct 6. No abstract available.

44.

Parallel reaction monitoring of clinical Mycobacterium tuberculosis lineages reveals pre-existent markers of rifampicin tolerance in the emerging Beijing lineage.

de Keijzer J, Mulder A, de Ru AH, van Soolingen D, van Veelen PA.

J Proteomics. 2017 Jan 6;150:9-17. doi: 10.1016/j.jprot.2016.08.022. Epub 2016 Aug 26.

PMID:
27576137
45.

Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers.

Alffenaar JC, Akkerman OW, Anthony RM, Tiberi S, Heysell S, Grobusch MP, Cobelens FG, Van Soolingen D.

Expert Rev Anti Infect Ther. 2017 Jan;15(1):11-21. Epub 2016 Oct 24. Review.

PMID:
27762157
46.

Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection.

Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6374-6. doi: 10.1128/AAC.00990-16. Print 2016 Oct.

47.

Use of RODAC plates to measure containment of Mycobacterium tuberculosis in a Class IIB biosafety cabinet during routine operations.

Daneau G, Nduwamahoro E, Fissette K, Rüdelsheim P, van Soolingen D, de Jong BC, Rigouts L.

Int J Mycobacteriol. 2016 Jun;5(2):148-54. doi: 10.1016/j.ijmyco.2016.01.003. Epub 2016 Feb 17.

48.

Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.

Ghimire S, Van't Boveneind-Vrubleuskaya N, Akkerman OW, de Lange WC, van Soolingen D, Kosterink JG, van der Werf TS, Wilffert B, Touw DJ, Alffenaar JW.

J Antimicrob Chemother. 2016 Oct;71(10):2691-703. doi: 10.1093/jac/dkw164. Epub 2016 May 26. Review.

PMID:
27231277
49.

Mycobacterium tuberculosis and Dual M. tuberculosis/M. bovis Infection as the Cause of Tuberculosis in a Gorilla and a Lioness, Respectively, in Ibadan Zoo, Nigeria.

Adeogun A, Omobowale O, Owuamanam C, Alaka O, Taiwo V, van Soolingen D, Cadmus S.

Case Rep Vet Med. 2016 May 15;2016:8568237. doi: 10.1155/2016/8568237. eCollection 2016.

50.

Nontuberculous Mycobacteria Isolated from Tuberculosis Suspects in Ibadan, Nigeria.

Cadmus SI, Diarra B, Traore B, Maiga M, Siddiqui S, Tounkara A, Falodun O, Lawal W, Adewole IF, Murphy R, van Soolingen D, Taiwo B.

J Pathog. 2016;2016:6547363. doi: 10.1155/2016/6547363. Epub 2016 Mar 23.

Supplemental Content

Loading ...
Support Center